SEOUL, South Korea–(BUSINESS WIRE)–ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, … [Read more…]
SEOUL, South Korea & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Gout–LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug ‘Tigulixostat’ (clinical program name: EURELIA_1 Study). LG Chem’s strategy is to expand its life sciences business and to reach … [Read more…]
NEW ‘Transparency Talks’ With Pfizer and Global Pricing Innovations (GPI) Help Pharmaceutical Companies Stay Compliant With Drug Pricing SAN MATEO, Calif.–(BUSINESS WIRE)–#LifeSciences—Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, today announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency … [Read more…]
SEATTLE–(BUSINESS WIRE)–Know Labs, Inc. (OTCQB: KNWN) an emerging developer of non-invasive medical diagnostic technology, today announced it has filed a Form S-1 registration statement for a proposed new offering of 3 million shares of its common stock with an anticipated offering price of $2.00 per share. Concurrent with, and as a condition to, the offering, … [Read more…]
AUSTIN, Texas–(BUSINESS WIRE)–Texas Original, Texas’ leading medical cannabis provider, announced that Kelly Roland has been promoted to president. Roland served as Texas Original’s senior vice president of sales and chief revenue officer for three years. During that time, she oversaw and drove the company’s rise to its commanding leadership position in Texas’ growing cannabis market. … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) will reconvene to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS). The second … [Read more…]
Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jaén and Granada, Spain. Since late … [Read more…]
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature’s Scientific Reports entitled “Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma”. The study was led by Dr. Cheng Liu, President and Chief … [Read more…]
PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022, at 1:45 p.m. Eastern Time. Investors and the general public are invited to access the … [Read more…]
Second-Quarter 2022 Results: — Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million — — GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million — — TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million — — KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Million — — Cash Position of … [Read more…]
